Recent Headlines
Within Biotechnology
AnaSpec Introduces CEF Control Peptide Pool
One of the world’s largest providers of catalog peptides, AnaSpec introduced its CEF Control Peptide Pool. Previously available only individually, this group of peptides is now available pooled. The CEF Control Peptide Pool is a group of 32 peptides, 8-12 amino acids in length, with... - August 23, 2007 - AnaSpec, EGT Group
AnaSpec Introduces 28 New Catalog Antibodies
Continuing in its commitment to rapidly expand its antibody offerings, AnaSpec, a leading provider of integrated proteomics solutions, added twenty-eight (28) new antibodies to its growing collection of catalog antibodies. - August 22, 2007 - AnaSpec, EGT Group
Sleep Study Suggests Magnetic Sleep Machine Promotes Deeper Sleep and Reduces Fibromyalgia Pain
Somnogram shows Sleep on Command™ Delta-rhythm magnetic signals help promote slow-wave, Delta-stage sleep throughout the night resulting in remarkable daytime pain relief in subject with fibromyalgia pain. - August 20, 2007 - EarthPulse Tech, LLC
Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Baxa Corporation announces the future 2008 training schedule for its professional Skills Training, Academics and Resources (STAR) Center for pharmacy and cleanroom skills training. Classes through the remainder of 2007 have been sold out since June. The first class in 2008 will be held January 22-24, with subsequent 2008 program dates: March 18-20, April 22-24 and June 17-19. - August 20, 2007 - Baxa Corporation
AnaSpec Introduces New 2007-2009 Combinatorial Chemistry Catalog
One of the world’s largest providers of unusual amino acids, today AnaSpec announced the release of its 2007-2009 Combinatorial Chemistry catalog. - August 18, 2007 - AnaSpec, EGT Group
"Overview of USP 797" Technical Paper by Baxa Corporation’s Mike Hurst Now Accessible on Expert411.com for Media and Professional Reference
The “Overview of USP 797” technical paper, authored by Baxa Corporation’s Mike Hurst, RPh, MBA, is now accessible at Expert411.com for media and professional reference. Most hospital pharmacists simply want to comply with the basic requirements of USP 797 and get on with the business of patient care. This paper is intended to help pharmacies get started in that direction. It also discusses USP 797 from several unique angles not necessarily considered in the initial literature. - August 15, 2007 - Baxa Corporation
Synergy Research Group and Promedica International Announce Global Network Alliance for Expansion of Global Clinical Trials Services
On August 2, 2007 Synergy Research Group (SynRG), a Russia based CRO with more than 5-years experience in clinical trials in Russia announced today the establishment of a new Global Network Alliance with Promedica International (PMI), a USA-based CRO. Promedica International (PMI), which... - August 04, 2007 - Synergy Research Group
Sarasota’s Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Findings Detailed in The Journal of Clinical Investigation: The Roskamp Institute today released a study defining a mechanism for the development of obesity and the metabolic syndrome, which are the forerunners of type 2 diabetes. The study, led by Roskamp’s Dr. Robert Farese, is detailed in the August issue of The Journal of Clinical Investigation, a highly prestigious medical research journal. - August 01, 2007 - Roskamp Institute
Analytical Results Highlight Efficacy of AnaSpec MOG Peptides
Reporting on results gathered from its antibody and assay kit departments, AnaSpec has released data that supports the efficacy of its MOG(35-55) peptide. Analytical results reported the following: AnaSpec’s mouse/rat MOG(35-55) peptide induced EAE in C57BL/6 mice with 100% incident (10/10). - July 28, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Acetylated and Methylated Lysines
AnaSpec has introduced acetylated, mono-methylated, di-methylated and tri-methylated Lysine for the synthesis of histone peptides. The use of these building blocks, although not limited to making synthetic histone peptides, provides additional tools for researchers to help unravel the... - July 28, 2007 - AnaSpec, EGT Group
Clinical Trials in Russia - 2nd Quarter 2007
On July 25, 2007 Synergy Research Group (SynRG), a Russia-based CRO, presented the current issue of its Orange Paper, a regular analytical report on the market of clinical trials in Russia. The report contains hundreds of figures as well as 11 Tables and 9 Pictures covering various aspects of the... - July 27, 2007 - Synergy Research Group
AnaSpec Introduces Fourteen New Catalog Peptides
Today AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced fourteen (14) new peptides for drug discovery research. HIV Nef (68–76) - Cat# 61673 This HIV nef peptide 68 to 76 amino acids was identified in HIV-infected individuals. It is a B7... - July 27, 2007 - AnaSpec, EGT Group
AnaSpec Introduces 12 New Catalog Antibodies
Continuing in its commitment to rapidly expand its antibody offerings, AnaSpec, a leading provider of integrated proteomics solutions, added twelve (12) new antibodies to its growing collection of catalog antibodies. The targeted research area for these antibodies is signal transduction and matrix... - July 26, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Ten New Catalog Peptides
Today AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced ten (10) new peptides for drug discovery research. MUC4 - Cat# 61339 This peptide is derived from the tandem repeat of Muc 4 mucin protein. Mucins are highly O-glycosylated proteins which... - July 25, 2007 - AnaSpec, EGT Group
Xcelience Expanding Operations
The Tampa-based contract research organization acquires a brand new building. - July 23, 2007 - Xcelience, LLC
AnaSpec Introduces Eleven New Catalog Peptides
This week AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced eleven (11) new peptides for drug discovery research. - July 22, 2007 - AnaSpec, EGT Group
AnaSpec Introduces New Selection of Cathelicidin Peptides
Cathelicidins are cationic peptides that have broad-range antimicrobial activity. These peptides belong to the family of anti-microbial peptides which form part of the host’s important innate immunity mechanism. - July 20, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Anti-MMP-1 & Anti-MMP-13 (Hinge) Antibodies
AnaSpec has introduced its newest antibody solutions – anti-MMP-1 (Hinge) and anti-MMP-13 (Hinge) antibodies. Strategically raised against the hinge regions of MMP-1 and MMP-13, the epitopes do not overlap the catalytic domain and will not influence the activity of the MMP ferment in... - July 19, 2007 - AnaSpec, EGT Group
Gamma Medica-Ideas Announces Sale of Flex TriumphTM Multi-Modality Pre-Clinical Imaging System to Université de Rouen
Gamma Medica-Ideas Inc. (GM-I), a leader in providing next-generation medical imaging devices for the pre-clinical and clinical markets, announced today that Université de Rouen in France has placed an order for a dual-modality Flex TriumphTM pre-clinical platform – including its... - July 19, 2007 - Gamma Medica-Ideas
“Premix vs. Custom TPN” Technical Paper Sponsored by Baxa Corporation Now Posted on Expert411.com for Media Access
The “Premix vs. Custom TPN” technical paper, sponsored by Baxa Corporation, is now available at Expert411.com for media and professional access. The paper, which provides a history of nutritional best practice and an examination of the use of premixed solutions for parenteral nutrition, is authored by Louis S. Diorio, RPh, and David L. Thomas, RPh MBA, both with Certified Consultant Pharmacists Healthcare Associates , Inc of Chatham, NJ. - July 18, 2007 - Baxa Corporation
Baxa Corporation Named One of Best Companies to Work for in Colorado
For the second year in a row, Englewood-based Baxa Corporation has been selected as one of Colorado’s best companies to work for; based on results from employee surveys by the Society for Human Resource Management (SHRM). Best Company finalists promote the best employment opportunities in the state – attracting new workers and promoting their retention. - July 16, 2007 - Baxa Corporation
American Peptide Symposium Poster Describes Synthesis of Hydrocarbon-Stapled Peptides
At the 2007 annual conference of the American Peptide Society, AnaSpec presented a technical poster that described the facile synthesis of a hydrocarbon-stapled peptide. Asymmetric synthesis of (S)-Fmoc-α-(2’-pentenyl)-alanine was successfully accomplished via an Ala-Ni (II)-BPB-complex... - July 14, 2007 - AnaSpec, EGT Group
AnaSpec Presents Late-Breaking In Vivo Imaging Poster at American Peptide Symposium
At the 2007 annual conference of the American Peptide Society, AnaSpec presented a “late-breaking” technical poster that described in vivo imaging using a tissue-specific near infrared fluorescent peptide conjugate. Extracellular matrix proteins that contain the Arg-Gly-Asp (RGD)... - July 13, 2007 - AnaSpec, EGT Group
Cornerstone BioPharma, Inc. and SJ Pharmaceuticals, LLC Sign Co-Promotion Agreement
Cornerstone BioPharma™, the Triangle-based specialty pharmaceutical company currently focused on the development and commercialization of niche prescription medications in the respiratory arena, today announced it has signed a co-promotion agreement with SJ Pharmaceuticals (SJP). This... - July 12, 2007 - Cornerstone BioPharma
Magellan BioScience Group, Inc. Awarded SBIR Grant for anti-Malarial Drug Discovery Collaboration with University of South Florida
Magellan BioScience Group, Inc. (Magellan), a pioneer in innovative drug discovery and development from marine microbial sources, and the University of South Florida (USF) announced today that they have been awarded a Phase I Small Business Innovative Research Grant (SBIR) from the National... - July 06, 2007 - CoreRx, Inc.
Baxa Corporation Features Pharmacy Training Programs, Abacus™ Software and ValiMed™ Medication Validation System at the ASHP Summer Meeting
Baxa Corporation is promoting its industry-leading STAR Center pharmacy training facility, CriticalPoint™ online sterile compounding certification training, Abacus TPN ordering and calculation software and the ValiMed System for medication validation at the American Society of Health-System Pharmacists 2007 Summer Meeting and Exhibition beginning today at the Moscone Center in San Francisco. - June 25, 2007 - Baxa Corporation
PharmaChem Publishes AnaSpec Article on Peptides as Antigens
The June issue of PharmaChem, an Italian journal covering the drug discovery industry, featured an article written by AnaSpec called “Peptides as Antigens.” The technical article, written by Dr. Daniel Li and Cecilia Po, outlines the advantages and methodologies behind using peptides as... - June 24, 2007 - AnaSpec, EGT Group
AnaSpec Introduces New SensoLyte™ Beta-Secretase Assay Kit
Leveraging one of the world’s largest collections of amyloid peptides, AnaSpec has introduced its latest development in novel solutions for amyloid-related research - the new SensoLyte™ 520 Beta-Secretase Assay Kit. Beta-secretase catalyzes a key step in the production of beta-amyloid... - June 22, 2007 - AnaSpec, EGT Group
Gamma Medica-Ideas Announces First Sale of a Dual-Head LumaGEM® Molecular Breast Imaging System
Gamma Medica-Ideas Inc. (GM-I), a leader in providing next-generation medical imaging devices for the pre-clinical and clinical markets, announced today the sale of a dual-headed LumaGEM® system for applications such as Molecular Breast Imaging (MBI). This dual head system is the first of its... - June 22, 2007 - Gamma Medica-Ideas
Baxa Corporation and Health Robotics Announce Strategic Alliance to Automate IV Admixture Preparation
Baxa Corporation and Health Robotics announce a strategic alliance to use the Baxa Two-Fer™ Needles with Health Robotics’ CytoCare™ Robot in order to safely and accurately automate the preparation of patient-specific chemotherapy IV admixtures. This alliance combines state-of-the-art technologies to achieve the accuracy and sterility that providers require. The resulting technology is the only totally automated system for handling hazardous IV admixtures available in the market. - June 18, 2007 - Baxa Corporation
University of Kuopio’s A.I. Virtanen Institute Uses Gamma Medica-Ideas’ FLEX Multi-Modality System to Image Baculovirus Biodistribution in Pre-Clinical Subjects
A team of researchers at University of Kuopio’s A.I Virtanen Institute for Molecular Sciences in Finland is conducting studies in non-invasive imaging with Gamma Medica-Ideas’ MicroSPECT/CT system to provide essential information on biodistribution of gene therapy vectors in rats. The... - June 17, 2007 - Gamma Medica-Ideas
Gamma Medica-Ideas Introduces High Resolution CT Subsystem
Gamma Medica-Ideas (GM-I) announced today the addition of a new High Resolution CT subsystem to the company’s FLEX Triumph™ Pre-clinical Imaging Platform that produces striking improvements in CT imaging. The new CT subsystem contains a variable focal spot x-ray source which provides... - June 17, 2007 - Gamma Medica-Ideas
Thrombotargets Corp. and Magellan Bioscience Group, Inc. to Collaborate on Identification of Novel Hits from Both Marine Derivate and Natural Products
Thrombotargets Corporation and Magellan Bioscience Group, Inc. today announced the formation of drug discovery joint venture. Under the terms of this agreement, Magellan Bioscience Group, Inc. will provide to Thrombotargets its compounds and extracts from fermentation broths of marine-isolated... - June 16, 2007 - CoreRx, Inc.
AnaSpec Introduces Industry’s First and Only Anti-MOG ELISA Kits
Drawing on its broad portfolio of MOG (35-55) and other multiple sclerosis (MS) experimental autoimmune encephalomyelitis (EAE)-related peptides, AnaSpec has just released its new line of SensoLyte™ Anti - MOG ELISA Kits - the industry’s first and only anti-MOG ELISA kits. Myelin... - June 16, 2007 - AnaSpec, EGT Group
ValiMed™ Medication Validation System And Related Information From Baxa Corporation Are Now Available At PublicRelationsNewsroom.com
The ValiMed Medication Validation System and related information are now available at PublicRelationsNewsroom.com. The ValiMed System, distributed by Baxa Corporation, offers clinicians a simple and cost-effective tool to ensure medication safety by verifying that medications are correctly compounded. Its patented technology validates compounded doses of high risk medications prior to dispensing. - June 15, 2007 - Baxa Corporation
Baxa Corporation Recognized by Medical Device & Design Industry Magazine for World-Class Quality Team
Baxa Corporation is profiled as one of eight world-class quality and regulatory teams in the June 2007 issue of Medical Device & Diagnostic Industry magazine. The June article was the first time MD&DI recognized the accomplishments of the quality and regulatory teams that ensure medical products are safe and ready for market. - June 13, 2007 - Baxa Corporation
AnaSpec Prepares Technical Poster about Beta-Secretase Assay for Experimental Biology 2007
At the 2007 Experimental Biology conference in Washington, DC, AnaSpec prepared a technical poster entitled, "A Sensitive Fluorimetric Assay for Detection of beta-Secretase Activity Using a Novel FRET Peptide Substrate." The poster documented the following findings: • A highly... - June 08, 2007 - AnaSpec, EGT Group
Clinical Trials in Russia. 1st Quarter 2007 Results
According to Synergy Research Group, a Russia-based CRO, the growth in the number of clinical trials approved by the Russian Federal Agency for Health Care and Social Development (Roszdravnadzor) made up to nearly 40% in the 1st Quarter of 2007 as compared to the same quarter of the previous year. At the same time, the share of clinical studies initiated by Russian manufacturers has increased. - June 06, 2007 - Synergy Research Group
Functional Genetics, Inc. Receives Award to Discover New Opportunities to Combat HIV Infection
Functional Genetics, Inc. Announces a New Award from the National Institute of Allergy and Infectious Diseases to Utilize Its Core Random Homozygous Gene Perturbation and Host-Oriented Therapeutics Technologies to Identify and Validate New Therapeutic Approaches to Combat HIV Infection - June 03, 2007 - Functional Genetics, Inc.
The Imminent Change of the Antithrombotics Market
The antithrombotics market with the two blockbusters enoxaparin and prasugrel is challenged by generic products as well as by next generation anticoagulants with oral administration and antithrombotics with an improved risk-benefit ratio - June 01, 2007 - La Merie Business Intelligence
Novel Agent for Reactive Metabolite Detection
Bioactivation of drug candidates resulting in chemically reactive, electrophilic metabolites have always presented a major challenge to pharmaceutical companies. Moreover, the measurement of these metabolites has been hampered by the lack of an effective quantitative method. QA-GSH is a novel new... - May 31, 2007 - AnaSpec, EGT Group
Colorado BioScience Association Applauds Governor Ritter’s Signing of HB 1060 As Critical To Future Growth of The State’s Bioscience Industry
Colorado Governor Bill Ritter signed House Bill 1060 into law Wednesday afternoon, with the bill sponsors present to acknowledge the importance of the legislation to the bioscience industry in Colorado. Rep. Jim Riesberg (D-Weld) and Sen. Brandon Shaffer (D-Longmont) were thanked for their efforts... - May 25, 2007 - Colorado BioScience Association
Xcelience Will Acquire New Technologies to Enhance Drug Development Processes
The Tampa-based Contract Research Organization signed a partnership that will form new opportunities in the pharmaceutical industry. - May 24, 2007 - Xcelience, LLC
AnaSpec Introduces Line of Insulin Receptor Antibodies
The insulin receptor is a transmembrane receptor that belongs to the tyrosine kinase receptors class. It is a heterotetrameric glycoprotein composed of disulfide-linked subunits in a β-α-α-β configuration. This transmembrane receptor consists of 95kDa β-subunit, a single... - May 23, 2007 - AnaSpec, EGT Group
Baxa Ltd, Subsidiary of Denver-based Baxa Corporation, Announces Direct Sales and Marketing Operations in Switzerland
Baxa Ltd, subsidiary of Denver-based Baxa Corporation, has moved to a direct sales and marketing model for the Swiss market. The company provides systems and devices for simplifying the handling, mixing and administration of fluid medications. Direct operations will provide Baxa Ltd with improved customer access for product development and continuous improvement, while continuing their excellent customer service. - May 21, 2007 - Baxa Corporation
Colorado BioScience Association Names Jack Wheeler Chairperson, Announces 2007 Sponsors and Appoints Eight New Board Members
Jack Wheeler, CEO of MicroPhage, Inc., Longmont, is the new chairperson of the board of directors for the Colorado BioScience Association (CBSA). He was appointed at the association’s 2007 annual meeting April 24th. Wheeler assumes chairperson responsibilities from Ed Wood, ArcScan, Inc. In other action, eight new board members were appointed to three-year terms. - May 18, 2007 - Colorado BioScience Association
Industry’s First West Nile Virus Protease Assay Kits
While West Nile virus (WNV) has had significant outbreaks throughout the world since it was first identified, commercially available assay kits for the detection of WNV protease inhibitors had not been developed until now. With the SensoLyte™ series of WNV Protease Assay Kits AnaSpec, a... - May 17, 2007 - AnaSpec, EGT Group
Baxa Corporation Wins BMA Colorado 2007 Gold Key Award
Baxa Corporation's direct marketing campaign for the Rapid-Fill™ Automated Syringe Filler was awarded a Business Marketing Association Gold Key in the Colorado Chapter’s 2007 competition. Three messages: Safety is Automatic, Technology that Fits and Designed for Speed emphasized the key attributes that differentiate the Baxa product from competitive products and processes. - May 16, 2007 - Baxa Corporation
Clinical Trials in Russia - First Issue of SynRG Orange Paper
On April 25, 2007, the first issue of the Orange Paper – the first analytical review on market of clinical trials in Russia – was officially presented. The strategic goals of Synergy Research Group, a Russia-based emerging CRO, are formation of a civilized market of clinical trials in... - May 16, 2007 - Synergy Research Group
Futuristic Sleep Machine Now Reality
Those seeking improved sleep can switch on Sleep on Command™ device designed to enforce Delta rhythm sleep and the recovery that best occurs during deep, slow-wave, Delta-stage sleep. - May 08, 2007 - EarthPulse Tech, LLC